BR122019020471B1 - Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas - Google Patents

Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas Download PDF

Info

Publication number
BR122019020471B1
BR122019020471B1 BR122019020471-3A BR122019020471A BR122019020471B1 BR 122019020471 B1 BR122019020471 B1 BR 122019020471B1 BR 122019020471 A BR122019020471 A BR 122019020471A BR 122019020471 B1 BR122019020471 B1 BR 122019020471B1
Authority
BR
Brazil
Prior art keywords
group
refers
term
alkyl
aryl
Prior art date
Application number
BR122019020471-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Alberto Ortega Munoz
Julio Castro-Palomino Laria
Matthew Colin Thor Fyfe
Original Assignee
Oryzon Genomics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics S.A. filed Critical Oryzon Genomics S.A.
Publication of BR122019020471B1 publication Critical patent/BR122019020471B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
BR122019020471-3A 2010-04-19 2011-04-19 Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas BR122019020471B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10160315.7 2010-04-19
EP10160315 2010-04-19
BR112012026694A BR112012026694A2 (pt) 2010-04-19 2011-04-19 inibidores da desmetilase específica para lisina 1 e seu uso
PCT/EP2011/056279 WO2011131697A1 (en) 2010-04-19 2011-04-19 Lysine specific demethylase-1 inhibitors and their use

Publications (1)

Publication Number Publication Date
BR122019020471B1 true BR122019020471B1 (pt) 2021-06-22

Family

ID=44280905

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012026694A BR112012026694A2 (pt) 2010-04-19 2011-04-19 inibidores da desmetilase específica para lisina 1 e seu uso
BR122019020471-3A BR122019020471B1 (pt) 2010-04-19 2011-04-19 Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012026694A BR112012026694A2 (pt) 2010-04-19 2011-04-19 inibidores da desmetilase específica para lisina 1 e seu uso

Country Status (22)

Country Link
US (3) US8722743B2 (https=)
EP (2) EP2560947B1 (https=)
JP (1) JP5868948B2 (https=)
KR (1) KR101794020B1 (https=)
CN (1) CN102947265B (https=)
AU (1) AU2011244325B2 (https=)
BR (2) BR112012026694A2 (https=)
CA (1) CA2796726C (https=)
CY (1) CY1118344T1 (https=)
DK (1) DK2560947T3 (https=)
ES (1) ES2607081T3 (https=)
HR (1) HRP20161748T1 (https=)
HU (1) HUE030938T2 (https=)
IL (1) IL222361A (https=)
LT (1) LT2560947T (https=)
MX (1) MX2012012111A (https=)
PL (1) PL2560947T3 (https=)
PT (1) PT2560947T (https=)
RS (1) RS55348B1 (https=)
RU (1) RU2599248C2 (https=)
SI (1) SI2560947T1 (https=)
WO (1) WO2011131697A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US20130303545A1 (en) * 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
US20140296255A1 (en) 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
US20140329833A1 (en) 2011-05-19 2014-11-06 Oryzon Genomics, S.A Lysine demethylase inhibitors for inflammatory diseases or conditions
JP6046154B2 (ja) * 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
EP2768805B1 (en) * 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2887598A1 (en) * 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
CN103242171A (zh) * 2013-05-09 2013-08-14 苏州明锐医药科技有限公司 反式-(1r,2s)-2-(3,4-二氟苯基)环丙胺的制备方法
ES2734209T3 (es) * 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
WO2015120281A1 (en) * 2014-02-07 2015-08-13 Musc Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MY180575A (en) 2014-04-11 2020-12-02 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
CA2976350C (en) 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
US9809541B2 (en) 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN107200706A (zh) * 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
RS58951B1 (sr) 2016-06-10 2019-08-30 Oryzon Genomics Sa Lečenje multiple skleroze
CN111194306B (zh) 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
MA51507A (fr) 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
US11433053B2 (en) 2017-01-24 2022-09-06 Medshine Discovery Inc. LSD1 inhibitor and preparation method and application thereof
JP2020152641A (ja) * 2017-07-07 2020-09-24 国立研究開発法人理化学研究所 リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
WO2019023350A1 (en) * 2017-07-26 2019-01-31 Sabic Global Technologies B.V. COMPOSITE SORBENT, DEVICES AND METHODS
FI3661510T3 (fi) 2017-08-03 2024-12-18 Oryzon Genomics Sa Menetelmiä käyttäytymismuutosten hoitamiseksi
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
EP3790867B1 (en) 2018-05-11 2024-03-27 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease
CA3106484C (en) * 2018-07-20 2024-06-25 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. A salt of an lsd1 inhibitor and its crystal form
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN112689638B (zh) 2018-09-13 2022-11-08 南昌弘益药业有限公司 作为lsd1抑制剂的环丙胺类化合物及其应用
LT3941466T (lt) 2019-03-20 2026-02-25 Oryzon Genomics, S.A. Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
IT202000007873A1 (it) * 2020-04-14 2021-10-14 St Europeo Di Oncologia S R L Molecole per uso nel trattamento delle infezioni virali
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
CN112451671B (zh) * 2020-12-02 2021-11-02 武汉大学 KDM1A在抑制RNA病毒刺激下干扰素IFNβ表达中的应用
CN113750095B (zh) * 2021-03-10 2023-07-04 中国医学科学院医药生物技术研究所 含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106578A (en) 1960-09-16 1963-10-08 Smith Kline French Lab Nu-phenethyl-2-phenylcyclopropylamine derivatives
US3365458A (en) 1964-06-23 1968-01-23 Aldrich Chem Co Inc N-aryl-n'-cyclopropyl-ethylene diamine derivatives
US3532749A (en) 1965-05-11 1970-10-06 Aldrich Chem Co Inc N'-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof
US3471522A (en) 1967-09-29 1969-10-07 Aldrich Chem Co Inc N-cyclopropyl-n'-furfuryl-n'-methyl ethylene diamines
US3532712A (en) 1967-09-29 1970-10-06 Aldrich Chem Co Inc N'-cyclopropyl ethylenediamine derivatives
US3654306A (en) 1970-01-26 1972-04-04 Robins Co Inc A H 5-azaspiro(2.4)heptane-4 6-diones
US3758684A (en) 1971-09-07 1973-09-11 Burroughs Wellcome Co Treating dna virus infections with amino purine derivatives
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4409243A (en) 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US20040132820A1 (en) 1996-02-15 2004-07-08 Jean Gosselin Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
GB9615730D0 (en) 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 1
US5961987A (en) 1996-10-31 1999-10-05 University Of Iowa Research Foundation Ocular protein stimulants
DE19647615A1 (de) 1996-11-18 1998-05-20 Bayer Ag Verfahren zur Herstellung von Cyclopropylaminen
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
WO1999031072A1 (en) 1997-12-18 1999-06-24 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
US6809120B1 (en) 1998-01-13 2004-10-26 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
SE9802206D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
JP2001354563A (ja) 2000-06-09 2001-12-25 Sankyo Co Ltd 置換ベンジルアミン類を含有する医薬
US8519005B2 (en) 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
DE10123163A1 (de) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
US20030008844A1 (en) 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
AU2003222786A1 (en) 2002-04-18 2003-10-27 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7611704B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
DE60318891T2 (de) 2002-12-13 2009-01-22 Smithkline Beecham Corp. Cyclopropylverbindungen als ccr5 antagonisten
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0303439D0 (en) 2003-02-14 2003-03-19 Pfizer Ltd Antiparasitic terpene alkaloids
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
ATE384039T1 (de) 2003-07-03 2008-02-15 Lilly Co Eli Indanderivate als muscarinrezeptoragonisten
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
ATE551997T1 (de) 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN1871008A (zh) 2003-10-21 2006-11-29 默克公司 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
RU2006125441A (ru) 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные циклопропана и их фармацевтическое применение
CA2551944A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
WO2005058808A1 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
US7399825B2 (en) 2003-12-24 2008-07-15 Lipps Binie V Synthetic peptide, inhibitor to DNA viruses
CA2564356A1 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
WO2006071608A2 (en) 2004-12-16 2006-07-06 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
ES2349544T3 (es) 2005-02-18 2011-01-04 Universitätsklinikum Freiburg Control de la expresión génica dependiente de receptores de andrógenos inhibiendo la actividad de amina oxidasa de la demetilasa lisina-específica (lsd1).
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US7273882B2 (en) 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2007021839A2 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2007025144A1 (en) 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
CN101466671B (zh) 2006-05-18 2012-01-11 先正达参股股份有限公司 杀微生物剂
US8198301B2 (en) 2006-07-05 2012-06-12 Hesheng Zhang Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
JP5140154B2 (ja) 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
PL2639226T3 (pl) 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
EP2215065B1 (en) 2007-10-19 2012-07-11 Boehringer Ingelheim International GmbH Ccr10 antagonists
CN101959900A (zh) 2007-12-26 2011-01-26 盐野义制药株式会社 糖肽类抗生素糖基化衍生物
WO2009109991A2 (en) 2008-01-23 2009-09-11 Sun Pharma Advanced Research Company Ltd., Novel hydrazide containing tyrosine kinase inhibitors
WO2009097278A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
RU2010142655A (ru) 2008-03-19 2012-04-27 Ауриммед Фарма, Инк. (Us) Соединение, пригодное для лечения болезней и нарушений центральной нервной системы, и способ его получения
CA2719735A1 (en) 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
US8972433B2 (en) 2008-04-18 2015-03-03 Travelport Operations, Inc. Systems and methods for programmatic generation of database statements
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
WO2010011845A2 (en) 2008-07-24 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010085749A2 (en) 2009-01-23 2010-07-29 Northwestern University Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
EP2467359A4 (en) 2009-08-18 2013-01-09 Univ Johns Hopkins (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011057262A2 (en) 2009-11-09 2011-05-12 Evolva Inc. Treatment of infections with tp receptor antagonists
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US20130197088A1 (en) 2010-03-12 2013-08-01 Robert A. Casero, JR. Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO)
CA2796726C (en) * 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112012027062B8 (pt) 2010-04-20 2021-05-25 Fond Ieo composto, processo para a preparação de um composto e usos do mesmo
CA2796504A1 (en) 2010-04-20 2011-10-27 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
CN103003231A (zh) 2010-06-30 2013-03-27 阿特维斯集团公司 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
US20140329833A1 (en) 2011-05-19 2014-11-06 Oryzon Genomics, S.A Lysine demethylase inhibitors for inflammatory diseases or conditions
US20140296255A1 (en) 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors

Also Published As

Publication number Publication date
SI2560947T1 (sl) 2017-01-31
EP2560947B1 (en) 2016-10-12
US10202330B2 (en) 2019-02-12
LT2560947T (lt) 2016-12-27
IL222361A0 (en) 2012-12-31
CN102947265B (zh) 2015-07-29
AU2011244325B2 (en) 2015-12-17
MX2012012111A (es) 2013-05-30
KR101794020B1 (ko) 2017-11-06
CY1118344T1 (el) 2017-06-28
DK2560947T3 (en) 2016-11-21
HRP20161748T1 (hr) 2017-02-10
JP2013525331A (ja) 2013-06-20
CA2796726C (en) 2021-02-16
RU2012148758A (ru) 2014-05-27
CA2796726A1 (en) 2011-10-27
US9149447B2 (en) 2015-10-06
RS55348B1 (sr) 2017-03-31
PL2560947T3 (pl) 2017-04-28
WO2011131697A1 (en) 2011-10-27
JP5868948B2 (ja) 2016-02-24
RU2599248C2 (ru) 2016-10-10
EP2560947A1 (en) 2013-02-27
PT2560947T (pt) 2016-11-24
AU2011244325A1 (en) 2012-12-06
IL222361A (en) 2015-08-31
US20150368186A1 (en) 2015-12-24
HUE030938T2 (en) 2017-06-28
KR20130059347A (ko) 2013-06-05
BR112012026694A2 (pt) 2016-07-12
EP3133059A1 (en) 2017-02-22
CN102947265A (zh) 2013-02-27
US20140213657A1 (en) 2014-07-31
ES2607081T3 (es) 2017-03-29
US20130090386A1 (en) 2013-04-11
US8722743B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
BR122019020471B1 (pt) Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas
EP2480528B1 (en) Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
EP2389362B1 (en) Phenylcyclopropylamine derivatives and their medical use
EP2361242B1 (en) Oxidase inhibitors and their use
BR112013002164B1 (pt) Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.